Drug Profile
Research programme: immunomodulatory therapeutics - Forward Pharma
Alternative Names: FP 219; FP 237; FP 289Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Forward Pharma
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Denmark
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Denmark
- 01 Oct 2008 Preclinical trials in Autoimmune disorders in Denmark (unspecified route)